October 3rd 2024
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.
September 20th 2024
September 19th 2024
September 18th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
First-Line Treatment Options and Subsequent Risks Facing Multiple Myeloma Patients
December 22nd 2020Saad Usmani, MD, discusses what first-line options are available for patients with multiple myeloma while highlighting the difficulties in defining high-risk characteristics associated with multiple myeloma.
Watch
FDA Biologics License Application for JZP-458 Initiated for 2 Leukemia Indications
December 21st 2020The submission of a Biologics License Application has been initiated seeking approval of JZP-458 as a part of a multi-agent chemotherapy regimen as treatment of adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity or silent inactivation to E. coli-derived asparaginases.
Read More
FDA Approves New Rituximab Biosimilar in NHL, CLL, and Other Hematologic Malignancies
December 18th 2020The FDA granted approval to rituximab-arrx, a biosimilar to rituximab as treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.
Read More
Different Staging, Risk Stratification, and Treatment Methods for Acute GVHD
December 17th 2020During a Targeted Oncology Case Based Peer Perspectives event, Miguel-Angel Perales, MD, discussed testing for risk stratification and treatment of graft-versus-host-disease based on the case of a 48-year-old man.
Read More
Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s Macroglobulinemia
December 15th 2020Christian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.
Watch
Benefit From MURANO Trial in CLL Sustained With Subsequent Therapy
December 9th 2020An analysis from the MURANO trial showed that venetoclax in combination with rituximab led to a more than doubling of time to next treatment compared with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Read More
REACH3 Study Demonstrates Promising Objective Responses in Chronic GVHD
December 8th 2020Robert Zeiser, MD, discusses the findings from the phase 3 REACH3 clinical trial of ruxolitinib as treatment of patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.
Watch
Significant Responses Seen With Investigational BTK Inhibitor in Pretreated CLL/SLL Population
December 8th 2020A high objective response rate was observed in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with LOXO-305, according to results of the phase 1/2 BRUIN trial presented during the 2020 ASH Annual Meeting.
Read More
Added Daratumumab Leads to Significant Hematologic Responses in Amyloidosis
December 8th 2020Results for the phase 3 ANDROMEDA study showed an improvement in hematologic complete response rates with the combination of daratumumab plus bortezomib, cyclophosphamide, and dexamethasone compared with VCd alone in patients with newly diagnosed amyloid light-chain amyloidosis.
Read More